• Plk1 Regulation of Mitotic Checkpoint Disassembly

  2026-10-10

  Kaisari and colleagues identify Polo-like kinase 1 (Plk1) as a negative regulator of p31comet-dependent mitotic checkpoint complex disassembly. Their evidence supports a phosphorylation-based mechanism in which Plk1 modifies p31comet at S102, helping prevent premature checkpoint inactivation during mitosis.

• Autophagy and Resveratrol-Induced Apoptosis in RCC

  2026-10-09

  Yao, Fan, and He show that resveratrol induces ROS-associated mitochondrial apoptosis and caspase-3 activation in renal cell carcinoma 786-O cells, while also triggering JNK-linked autophagy. The study’s central contribution is the evidence that autophagy functions as a protective response in this model, creating a rationale for investigating resveratrol alongside autophagy inhibition without establishing clinical efficacy.

• DOTAP and RNA-LNP Stability: An Evidence Framework

  2026-10-09

  Explore how 1,2-Dioleoyl-3-trimethylammonium-propane chloride (DOTAP) connects charge-mediated nucleic acid delivery with RNA-LNP stability research. This evidence-focused analysis interprets a 2025 spray-drying study while defining the limits of translating formulation findings to transfection and functional genomics.

• Linezolid and Emerging Antimicrobial Research Context

  2026-10-08

  Linezolid is an oxazolidinone antimicrobial used in research on Gram-positive bacterial infections, while a 2024 Bioorganic Chemistry study describes a separate spirocyclic POM chemotype targeting MmpL3 in Mycobacterium tuberculosis. Their findings illustrate why assay type, target evidence, clinical relevance, and study provenance must be evaluated separately.

• Carbapenemase Gene Spread in CREC, 2022–2024

  2026-10-08

  Chen et al. characterize carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates collected from eight teaching hospitals in Guangdong, China. The study links frequent blaNDM-1 carriage, high apparent transferability, multidrug resistance, mobile genetic elements, and diverse strain genotypes, while also showing why laboratory evidence should not be equated automatically with documented hospital transmission.

• Ampicillin sodium: Evidence Beyond the MIC

  2026-10-07

  Ampicillin sodium is more than a β-lactam antibiotic benchmark: it can also illuminate how assay context, recombinant protein workflows, and evidence provenance shape interpretation. This article connects antibacterial mechanism with a classic annexin V purification study while defining practical limits on cross-study conclusions.

• Sumatriptan as an Anti-Inflammatory: Evidence Review

  2026-10-07

  Ala et al. synthesized 66 studies examining whether sumatriptan has anti-inflammatory effects beyond its established use in migraine and cluster headache. The review links 5-HT1B/1D signaling with changes in cytokines, nitric oxide pathways, calciton gene-related peptide release, and tissue-injury models, while emphasizing that heterogeneous preclinical evidence does not yet establish a broad anti-inflammatory indication.

• LLY-507 and SMYD2 Inhibition: Evidence and Limits

  2026-10-06

  LLY-507 is a research SMYD2 inhibitor used to investigate lysine methylation in cancer biology and renal fibrosis. Available evidence includes supplier-reported biochemical and cellular activity and a 2023 preclinical study of SMYD2 inhibition in cisplatin-induced renal disease, but clinical relevance, long-term safety, and broad disease applicability remain unestablished.

• BPN-19186 in the sEH–Nrf2 Bone Research Context

  2026-10-06

  This overview examines the research context surrounding BPN-19186, also known as (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea, in relation to soluble epoxide hydrolase, Nrf2 signaling, and osteoclastogenesis. It distinguishes supplier-reported compound information from findings in a recent pre-proof study and emphasizes evidence strength, provenance, and applicability limits.

• NF-κB–Apaf1 Axis in Septic Acute Kidney Injury

  2026-10-05

  A 2026 study identifies an NF-κB/Apaf1/caspase-9 pathway that links inflammatory signaling to impaired autophagy, tubular apoptosis, and renal dysfunction in experimental septic acute kidney injury. Its genetic and pharmacological evidence supports Apaf1 and caspase-9 as mechanistic nodes, while the findings remain bounded by the use of LPS-based mouse and cell models.

• KPT-330 and XPO1 Inhibition in Osteoarthritis Research

  2026-10-05

  KPT-330, also known as Selinexor, is best known as a selective XPO1/CRM1 inhibitor in cancer research. A 2026 iScience study extends that context to osteoarthritis, reporting reduced osteoclastogenesis, improved subchondral bone features, and cartilage preservation in cellular and mouse models. The findings are promising but remain preclinical, model-dependent, and insufficient to establish clinical efficacy or safety in osteoarthritis.

• Bazedoxifene and Hemozoin: An Antimalarial Study

  2026-10-04

  Sudhakar et al. examined three selective estrogen receptor modulators and identified bazedoxifene as the strongest antimalarial candidate, with activity against Plasmodium falciparum and reduced P. berghei infection in female mice. The study connects this activity to impaired hemozoin formation, while also showing that host sex can influence in vivo efficacy and that the findings remain preclinical.

• Levofloxacin: Research Context and Evidence

  2026-10-03

  Levofloxacin is a synthetic fluoroquinolone antibiotic used to investigate bacterial DNA replication and selected bone-cell responses. This overview separates supplier-reported findings from peer-reviewed evidence, compares conceptual applications, and explains limitations in translating osteoblast or cartilage observations across models.

• G-1: Selective GPR30 Agonist Workflows

  2026-10-01

  G-1 enables controlled interrogation of GPR30/GPER1 signaling across calcium, PIP3, migration, cardiovascular, and pain-model assays. This workflow-focused guide emphasizes receptor-specific controls, solubility management, and the crucial distinction between pharmacologic activation and the GPR30 inhibition used in spinal neuropathic-pain research.

• Cefodizime in Applied Microbiology Research

  2026-10-01

  Cefodizime combines measurable β-lactam activity with a workflow-friendly profile for bacterial susceptibility, resistance, and host–pathogen studies. This guide translates its PBP-directed mechanism, organism-specific MIC data, and formulation constraints into practical assay choices and troubleshooting steps.

8141 records 2/543 page Previous Next 12345 下5页 Last page